CATRIDECACOG (Novothirteen ®)
Clinical Indication
Long term prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency and bleeding episodes during regular prophylaxis.
Date of classification
September 2022
Grey
Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.
- New medicines, devices, appliances.
- New indication of existing medicine.
- New NICE TA which has not been reviewed.
- Not been requested for review by either TAS/LPT MMC.